Abstract
Prostate cancer is the most common malignant neoplasm in men, excluding non-melanoma skin tumors, accounting for approximately 25% of the new cancers diagnosed in the Brazilian male population. Radioligand therapies have shown promise in the treatment of specific neoplasms. Lutetium-177 labeled PSMA (177Lu-PSMA-617) has been used for patients with metastatic carcinoma resistant to chemica…